[Kawasaki disease. Treatment with intravenous gammaglobulins]

Area of Science:

• Pediatrics
• Immunology
• Cardiology

Background:

• Kawasaki disease is an acute febrile illness primarily affecting young children.
• Coronary artery abnormalities, including aneurysms, are a significant complication.
• Intravenous immunoglobulin (IVIG) is a standard treatment, but modified forms are being explored.

Purpose of the Study:

• To evaluate the efficacy of plasmin-modified immunoglobulins in treating acute Kawasaki disease.
• To assess the impact of this treatment on clinical symptoms, laboratory markers, and coronary artery outcomes.

Main Methods:

• Thirty French children with acute Kawasaki disease received high-dose intravenous plasmin-modified immunoglobulins (1-2.5 g/kg).
• Clinical symptoms, laboratory parameters (hyperfibrinogenemia, leukocytosis, thrombocytosis), and immunological markers were monitored.
• Echocardiography and coronary arteriography were used to assess coronary artery status.

Main Results:

• Rapid resolution of clinical symptoms was observed in all patients.
• Hyperfibrinogenemia, hyperleukocytosis, and thrombocytosis regressed within 1-3 weeks.
• Only one child showed transient left coronary artery dilatation; coronary arteriography was normal at 6 months, indicating prevention of aneurysms.

Conclusions:

• High-dose intravenous plasmin-modified immunoglobulins are effective in treating acute Kawasaki disease.
• This therapy appears to prevent the development of coronary artery aneurysms.
• The immunoregulatory properties of immunoglobulins underpin their therapeutic value in immune-mediated conditions.